Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600538'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1994.74 Med: -19.33 Max: 366.85
Current: -28.48
During the past 13 years, the highest EV-to-EBIT of Beihai Gofar Chuanshan Biological Co was 366.85. The lowest was -1994.74. And the median was -19.33.
SHSE:600538's EV-to-EBIT is ranked worse than 100% of 202
companies
in the Agriculture industry
Industry Median: 12.27
vs SHSE:600538: -28.48
Beihai Gofar Chuanshan Biological Co (SHSE:600538) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Beihai Gofar Chuanshan Biological Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥3,128.3 Mil.
Beihai Gofar Chuanshan Biological Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-87.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beihai Gofar Chuanshan Biological Co EV-to-EBIT Related Terms
Beihai Gofar Chuanshan Biological Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beihai Gofar Chuanshan Biological Co EV-to-EBIT Chart
SHSE:600538 vs CTVA, CF, MOS: EV-to-EBIT Comparison
For the Agricultural Inputs subindustry, Beihai Gofar Chuanshan Biological Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beihai Gofar Chuanshan Biological Co EV-to-EBIT vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Beihai Gofar Chuanshan Biological Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beihai Gofar Chuanshan Biological Co's EV-to-EBIT falls into.
Beihai Gofar Chuanshan Biological Co's current Enterprise Value is ¥2,489.0 Mil.
Beihai Gofar Chuanshan Biological Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-87.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beihai Gofar Chuanshan Biological Co (SHSE:600538) has a EV-to-EBIT of -28.48 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beihai Gofar Chuanshan Biological Co and its competitors. According to the industry distribution chart, Beihai Gofar Chuanshan Biological Co ranks #999999 out of 202 companies in the Agriculture industry.
Is Beihai Gofar Chuanshan Biological Co's EV-to-EBIT too high?
Beihai Gofar Chuanshan Biological Co's current EV-to-EBIT is -28.48. Based on the distribution chart, Beihai Gofar Chuanshan Biological Co ranks #999999 out of 202 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Beihai Gofar Chuanshan Biological Co has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beihai Gofar Chuanshan Biological Co's EV-to-EBIT compare to CTVA and CF?
According to the Agriculture industry distribution chart, Beihai Gofar Chuanshan Biological Co ranks #999999 out of 202 companies for EV-to-EBIT. This places Beihai Gofar Chuanshan Biological Co in the lower half of its industry. The industry median EV-to-EBIT is 12.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for an Agriculture company?
The median EV-to-EBIT among Agriculture companies is 12.27, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beihai Gofar Chuanshan Biological Co and its competitors. For the Agriculture industry, the median EV-to-EBIT is 12.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beihai Gofar Chuanshan Biological Co's current EV-to-EBIT is -28.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beihai Gofar Chuanshan Biological Co stock overvalued right now?
Based on GuruFocus' analysis, Beihai Gofar Chuanshan Biological Co (SHSE:600538) is currently considered Fairly Valued. The stock's GF Value™ is ¥4.67, compared to a current price of ¥4.85 — trading 3.9% above its estimated fair value. The current EV-to-EBIT is -28.48. Beihai Gofar Chuanshan Biological Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Beihai Gofar Chuanshan Biological Co (SHSE:600538), the current EV-to-EBIT is -28.48 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beihai Gofar Chuanshan Biological Co (SHSE:600538) Overvalued in 2026?
Based on GuruFocus' analysis, Beihai Gofar Chuanshan Biological Co stock appears to be overvalued.
The current stock price of ¥4.85 is trading 3.9% above its estimated GF Value™ of ¥4.67.
GuruFocus considers Beihai Gofar Chuanshan Biological Co to be Fairly Valued.
Key valuation signals for SHSE:600538:
EV-to-EBIT: -28.48
GF Value™: ¥4.67 vs. price of ¥4.85 (3.9% above fair value)
No single metric tells the full story. See the SHSE:600538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beihai Gofar Chuanshan Biological Co Ltd main business include pharmaceutical manufacturing and pharmaceutical distribution industry, judicial IVD (in vitro diagnostic) technology services, molecular medical imaging centers and tumor radiotherapy centers and tumor telemedicine technology services, etc.
53GF Score
Get the complete analysis for SHSE:600538
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600538 has been successfully added to your 
